Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
Avatar

2019 SOHO Updates on CML: Frontline Therapy is Good, Getting Better and Safer, 2nd Line Options Grossly Equivalent, 3rd Line Ponatinib is Better, Complete Cytogenetic Response Improves Survival

By Xth Eurasian Hematology-Oncology Congress FEATURING Elias Jabbour
By Xth Eurasian Hematology-Oncology Congress FEATURING Elias Jabbour
0 views
December 13, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Hematologic Oncology
10:05
Xth Eurasian Hematology-Oncology Congress

Best Abstract Presentation (Francesco Lo Coco Prize) - Adult Hematol…

Feat. M. Ozbalak
07:09
Xth Eurasian Hematology-Oncology Congress

Best Abstract Presentation (Ekrem Muftuoglu Prize) - Oncology Evalua…

Feat. S. Çelik
10:30
Xth Eurasian Hematology-Oncology Congress

Best Abstract Presentation (Atilla Yalcin Prize) - Transplant Is The…

Feat. P. Kaloyannidis
21:36
Xth Eurasian Hematology-Oncology Congress

How I Treat Multiple Myeloma

Feat. A. Maiolino
22:57
Xth Eurasian Hematology-Oncology Congress

Importance of MRD in Multiple Myeloma: Can MRD Guide Therapy in Newl…

Feat. E. Terpos
18:10
Xth Eurasian Hematology-Oncology Congress

Impact of Continuous First-Line Therapy in the Treatment of the Firs…

Feat. A. Ibrahim
23:38
Xth Eurasian Hematology-Oncology Congress

Therapeutic Modulation of The Pleural Effusion Environment: the Next…

Feat. V. Donnenberg
18:57
Xth Eurasian Hematology-Oncology Congress

The Secretome of Malignant Effusions: The IL-6/sIL-6Ra Axis Appears …

Feat. A. Donnenberg
24:57
Xth Eurasian Hematology-Oncology Congress

Are Maintenance Post-transplant Therapies Needed: Hypomethylating Ag…

Feat. K. Halahleh
20:18
Xth Eurasian Hematology-Oncology Congress

Will CAR T-cell Therapy Replace HSCT? The Use of CAR-T Could Further…

Feat. F. Saglio
25:14
Xth Eurasian Hematology-Oncology Congress

Oral Chronic GVHD Is Common Disease and May Persist for Years, Manag…

Feat. N. Treister
10:40
Xth Eurasian Hematology-Oncology Congress

Analysis of PFS in CLL: Pts Who Received First-Line Bendamustine-Rit…

Feat. I. Miroliubova
11:45
Xth Eurasian Hematology-Oncology Congress

Prognostic Implication of NOTCH 1 Expression Among Adult Patients wi…

Feat. G. Elyamany
16:28
Xth Eurasian Hematology-Oncology Congress

2019 SOHO Update on AML: FLT3 and IDH1/2 Inhibitors, Venetoclax, Ant…

Feat. G. Garcia-Manero
21:46
Xth Eurasian Hematology-Oncology Congress

Personalizing Prognosis and Treatment of MPN: Historical Milestones …

Feat. T. Mughal
23:03
Xth Eurasian Hematology-Oncology Congress

The Best Example of Precision Oncology in CML: Response to TKI Thera…

Feat. G. Saglio
22:56
Xth Eurasian Hematology-Oncology Congress

Precision Oncology in MDS: We Still Don't Know Precise Mechanis…

Feat. M. Çetiner
15:40
Xth Eurasian Hematology-Oncology Congress

2019 SOHO Update on ALL: Ponatinib -Blinatumomab in Ph+, Ino / Blina…

Feat. E. Jabbour
14:17
Xth Eurasian Hematology-Oncology Congress

2019 SOHO Updates on CML: Frontline Therapy is Good, Getting Better …

Feat. E. Jabbour
19:17
Xth Eurasian Hematology-Oncology Congress

2019 SOHO Updates on MDS: Treatment of CHIP, New Approach for Anemia…

Feat. G. Garcia-Manero
16:04
Xth Eurasian Hematology-Oncology Congress

St-Petersburg Hematological Centre Experience on the Use of BMT in R…

Feat. N. Mikhailova
14:22
Xth Eurasian Hematology-Oncology Congress

Kirov Hematological Institute Analysis of Donors Register: Unrelated…

Feat. M. Loginova
13:40
Xth Eurasian Hematology-Oncology Congress

Bone Marrow Allogenic Transplantation in Relapsed/ Refractory Hem Ma…

Feat. I. Moiseev
20:34
Xth Eurasian Hematology-Oncology Congress

Should ALL Treatment be Driven by MRD Detection? IOs Result in Highe…

Feat. D. Hoelzer
20:45
Xth Eurasian Hematology-Oncology Congress

2019 Therapy of Ph+ ALL: Which TKIs, Dosing and Schedule, Intensity,…

Feat. O. Ottmann
12:21
Xth Eurasian Hematology-Oncology Congress

Ph-like ALL Should Be Treated as the Other B ALL After Demonstration…

Feat. O. Ottmann
24:55
Xth Eurasian Hematology-Oncology Congress

Overview of Current Therapeutic Options in AML of Young Adults: New …

Feat. M. Yilmaz
22:53
Xth Eurasian Hematology-Oncology Congress

Risk Stratification and Treatment of CLL: If New Drugs Available, 17…

Feat. R. Foa
22:05
Xth Eurasian Hematology-Oncology Congress

Therapeutic Approach for CLL Biomarkers: Low-Risk Should Be Treated …

Feat. P. Panayiotidis
22:53
Xth Eurasian Hematology-Oncology Congress

New Drugs Have an Established Role in CLL: BCR and BCL2 Inhibitors (…

Feat. R. Foa
13:19
Xth Eurasian Hematology-Oncology Congress

Moscow National Hematological Centre Experience on the Role and Plac…

Feat. L. Mendeleeva, M. Solovev
07:20
Xth Eurasian Hematology-Oncology Congress

Ph-like ALL Therapy Should Be Different From the Other B-ALL: Target…

Feat. D. Hoelzer
23:09
Xth Eurasian Hematology-Oncology Congress

Hemostasis Changes in Paroxysmal Nocturnal Hemoglobinuria: Is PNH a …

Feat. P. Toulon
26:52
Xth Eurasian Hematology-Oncology Congress

Managing Paroxysmal Nocturnal Hemoglobinuria: Chronic Complement-Med…

Feat. B. Antmen
21:11
Xth Eurasian Hematology-Oncology Congress

Eosinophilia and Mastocytosis: TKIs are SOC for PDGFRa/b Mutations, …

Feat. H. Hamed
19:25
Xth Eurasian Hematology-Oncology Congress

Approaching Consensus in Immune Thrombocytopenic Purpura: Adult ITP …

Feat. D. Provan